Travis J Osterman1, May Terry2, Robert S Miller3. 1. Departments of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, TN. 2. MITRE Corporation, Bedford, MA. 3. CancerLinQ, ASCO, Alexandria, VA.
Abstract
PURPOSE: Because of expanding interoperability requirements, structured patient data are increasingly available in electronic health records. Many oncology data elements (eg, staging, biomarkers, documentation of adverse events and cancer outcomes) remain challenging. The Minimal Common Oncology Data Elements (mCODE) project is a consensus data standard created to facilitate transmission of data of patients with cancer. METHODS: In 2018, mCODE was developed through a work group convened by ASCO, including oncologists, informaticians, researchers, and experts in terminologies and standards. The mCODE specification is organized by 6 high-level domains: patient, laboratory/vital, disease, genomics, treatment, and outcome. In total, 23 mCODE profiles are composed of 90 data elements. RESULTS: A conceptual model was published for public comment in January 2019 and, after additional refinement, the first public version of the mCODE (version 0.9.1) Fast Healthcare Interoperability Resources (FHIR) implementation guide (IG) was presented at the ASCO Annual Meeting in June 2019. The specification was approved for balloting by Health Level 7 International (HL7) in August 2019. mCODE passed the HL7 ballot in September 2019 with 86.5% approval. The mCODE IG authors worked with HL7 reviewers to resolve all negative comments, leading to a modest expansion in the number of data elements and tighter alignment with FHIR and other HL7 conventions. The mCODE version 1.0 FHIR IG Standard for Trial Use was formally published on March 18, 2020. CONCLUSION: The mCODE project has the potential to offer tremendous benefits to cancer care delivery and research by creating an infrastructure to better share patient data. mCODE is available free from www.mCODEinitiative.org. Pilot implementations are underway, and a robust community of stakeholders has been assembled across the oncology ecosystem.
PURPOSE: Because of expanding interoperability requirements, structured patient data are increasingly available in electronic health records. Many oncology data elements (eg, staging, biomarkers, documentation of adverse events and cancer outcomes) remain challenging. The Minimal Common Oncology Data Elements (mCODE) project is a consensus data standard created to facilitate transmission of data of patients with cancer. METHODS: In 2018, mCODE was developed through a work group convened by ASCO, including oncologists, informaticians, researchers, and experts in terminologies and standards. The mCODE specification is organized by 6 high-level domains: patient, laboratory/vital, disease, genomics, treatment, and outcome. In total, 23 mCODE profiles are composed of 90 data elements. RESULTS: A conceptual model was published for public comment in January 2019 and, after additional refinement, the first public version of the mCODE (version 0.9.1) Fast Healthcare Interoperability Resources (FHIR) implementation guide (IG) was presented at the ASCO Annual Meeting in June 2019. The specification was approved for balloting by Health Level 7 International (HL7) in August 2019. mCODE passed the HL7 ballot in September 2019 with 86.5% approval. The mCODE IG authors worked with HL7 reviewers to resolve all negative comments, leading to a modest expansion in the number of data elements and tighter alignment with FHIR and other HL7 conventions. The mCODE version 1.0 FHIR IG Standard for Trial Use was formally published on March 18, 2020. CONCLUSION: The mCODE project has the potential to offer tremendous benefits to cancer care delivery and research by creating an infrastructure to better share patient data. mCODE is available free from www.mCODEinitiative.org. Pilot implementations are underway, and a robust community of stakeholders has been assembled across the oncology ecosystem.
Authors: Monica M Bertagnolli; Brian Anderson; Kelly Norsworthy; Steven Piantadosi; Andre Quina; Richard L Schilsky; Robert S Miller; Sean Khozin Journal: J Clin Oncol Date: 2020-03-25 Impact factor: 44.544
Authors: Amy P Abernethy; Lynn M Etheredge; Patricia A Ganz; Paul Wallace; Robert R German; Chalapathy Neti; Peter B Bach; Sharon B Murphy Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: David A Chambers; Eitan Amir; Ramy R Saleh; Danielle Rodin; Nancy L Keating; Travis J Osterman; James L Chen Journal: Am Soc Clin Oncol Educ Book Date: 2019-05-17
Authors: Jeremy L Warner; Suzanne E Maddux; Kevin S Hughes; John C Krauss; Peter Paul Yu; Lawrence N Shulman; Deborah K Mayer; Mike Hogarth; Mark Shafarman; Allison Stover Fiscalini; Laura Esserman; Liora Alschuler; George Augustine Koromia; Zabrina Gonzaga; Edward P Ambinder Journal: J Am Med Inform Assoc Date: 2015-01-20 Impact factor: 4.497
Authors: Richard L Schilsky; Dina L Michels; Amy H Kearbey; Peter Paul Yu; Clifford A Hudis Journal: J Clin Oncol Date: 2014-06-09 Impact factor: 44.544
Authors: Hamid Emamekhoo; Cibele B Carroll; Chelsea Stietz; Jeffrey B Pier; Michael D Lavitschke; Daniel Mulkerin; Mary E Sesto; Amye J Tevaarwerk Journal: JCO Clin Cancer Inform Date: 2022-06
Authors: Stephany N Duda; Nan Kennedy; Douglas Conway; Alex C Cheng; Viet Nguyen; Teresa Zayas-Cabán; Paul A Harris Journal: J Am Med Inform Assoc Date: 2022-08-16 Impact factor: 7.942
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2022-05 Impact factor: 30.153
Authors: Lori A Pollack; Sandra F Jones; Wendy Blumenthal; Temitope O Alimi; David E Jones; Joseph D Rogers; Vicki B Benard; Lisa C Richardson Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Danielle Potter; Raven Brothers; Andrej Kolacevski; Jacob E Koskimaki; Amy McNutt; Robert S Miller; Jatin Nagda; Anil Nair; Wendy S Rubinstein; Andrew K Stewart; Iris J Trieb; George A Komatsoulis Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Daniel X Yang; Rohan Khera; Joseph A Miccio; Vikram Jairam; Enoch Chang; James B Yu; Henry S Park; Harlan M Krumholz; Sanjay Aneja Journal: JAMA Netw Open Date: 2021-03-01